151 related articles for article (PubMed ID: 37480941)
1. A Summary of the Rare Reports of Osteonecrosis of the Jaw Associated With Tumor Necrosis-α Inhibitors in the United States Food and Drug Administration's Adverse Event Reporting System Database.
Wichelmann TA; Ahdi HS; Pandravada S; Ehrenpreis ED
J Oral Maxillofac Surg; 2023 Oct; 81(10):1311-1318. PubMed ID: 37480941
[TBL] [Abstract][Full Text] [Related]
2. Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS).
Ahdi HS; Wichelmann TA; Pandravada S; Ehrenpreis ED
BMC Pharmacol Toxicol; 2023 Mar; 24(1):15. PubMed ID: 36879299
[TBL] [Abstract][Full Text] [Related]
3. Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS).
Zhang X; Hamadeh IS; Song S; Katz J; Moreb JS; Langaee TY; Lesko LJ; Gong Y
J Bone Miner Res; 2016 Feb; 31(2):336-40. PubMed ID: 26288087
[TBL] [Abstract][Full Text] [Related]
4. Real-world study of antiresorptive-related osteonecrosis of jaw based on the US food and drug administration adverse event reporting system database.
Peng J; Wang H; Liu Z; Xu ZL; Wang MX; Chen QM; Wu ML; Ren XL; Liang QH; Liu FP; Ban B
Front Pharmacol; 2022; 13():1017391. PubMed ID: 36339548
[No Abstract] [Full Text] [Related]
5. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
6. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
[TBL] [Abstract][Full Text] [Related]
7. Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis.
Everts-Graber J; Lehmann D; Burkard JP; Schaller B; Gahl B; Häuselmann H; Studer U; Ziswiler HR; Reichenbach S; Lehmann T
J Bone Miner Res; 2022 Feb; 37(2):340-348. PubMed ID: 34787342
[TBL] [Abstract][Full Text] [Related]
8. Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database.
de Boissieu P; Kanagaratnam L; Abou Taam M; Roux MP; Dramé M; Trenque T
Pharmacoepidemiol Drug Saf; 2014 Sep; 23(9):989-92. PubMed ID: 24737486
[TBL] [Abstract][Full Text] [Related]
9. Denosumab-associated osteonecrosis of the jaw affects osteoclast formation and differentiation: Pathological features of two cases.
Matsushita Y; Hayashida S; Morishita K; Sakamoto H; Naruse T; Sakamoto Y; Yamada SI; Yanamoto S; Fujita S; Ikeda T; Umeda M
Mol Clin Oncol; 2016 Feb; 4(2):191-194. PubMed ID: 26893859
[TBL] [Abstract][Full Text] [Related]
10. A Large National Cohort Study of the Association between Bisphosphonates and Osteonecrosis of the Jaw in Patients with Osteoporosis: A Nested Case-control Study.
Kwon JW; Park EJ; Jung SY; Sohn HS; Ryu H; Suh HS
J Dent Res; 2015 Sep; 94(9 Suppl):212S-9S. PubMed ID: 26001708
[TBL] [Abstract][Full Text] [Related]
11. Ischaemic colitis in rheumatoid arthritis patients receiving tumour necrosis factor-α inhibitors: an analysis of reports to the US FDA Adverse Event Reporting System.
Salk A; Stobaugh DJ; Deepak P; Ehrenpreis ED
Drug Saf; 2013 May; 36(5):329-34. PubMed ID: 23580194
[TBL] [Abstract][Full Text] [Related]
12. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease.
Sivolella S; Lumachi F; Stellini E; Favero L
Anticancer Res; 2013 May; 33(5):1793-7. PubMed ID: 23645723
[TBL] [Abstract][Full Text] [Related]
13. Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator-mandated cohort postauthorization safety study in Denmark, Norway, and Sweden.
Ehrenstein V; Heide-Jørgensen U; Schiødt M; Akre O; Herlofson BB; Hansen S; Larsson Wexell C; Nørholt SE; Tretli S; Kjellman A; Glennane A; Lowe KA; Sørensen HT
Cancer; 2021 Nov; 127(21):4050-4058. PubMed ID: 34310704
[TBL] [Abstract][Full Text] [Related]
14. Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan.
Liu FC; Luk KC; Chen YC
Osteoporos Int; 2023 Oct; 34(10):1729-1737. PubMed ID: 37326685
[TBL] [Abstract][Full Text] [Related]
15. Identification of Risk Factors for Bisphosphonate-Associated Atypical Femoral Fractures and Osteonecrosis of the Jaw in a Pharmacovigilance Database.
Bejhed RS; Kharazmi M; Hallberg P
Ann Pharmacother; 2016 Aug; 50(8):616-24. PubMed ID: 27179251
[TBL] [Abstract][Full Text] [Related]
16. Osteonecrosis and osteomyelitis of the jaw associated with tumour necrosis factor-alpha (TNF-α) inhibitors: a systematic review.
Sacco R; Shah S; Leeson R; Moraschini V; de Almeida Barros Mourão CF; Akintola O; Lalli A
Br J Oral Maxillofac Surg; 2020 Jan; 58(1):25-33. PubMed ID: 31645276
[TBL] [Abstract][Full Text] [Related]
17. Assessing the likelihood of new-onset inflammatory bowel disease following tumor necrosis factor-alpha inhibitor therapy for rheumatoid arthritis and juvenile rheumatoid arthritis.
Krishnan A; Stobaugh DJ; Deepak P
Rheumatol Int; 2015 Apr; 35(4):661-8. PubMed ID: 25228459
[TBL] [Abstract][Full Text] [Related]
18. Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System.
Deepak P; Stobaugh DJ; Sherid M; Sifuentes H; Ehrenpreis ED
Aliment Pharmacol Ther; 2013 Aug; 38(4):388-96. PubMed ID: 23802849
[TBL] [Abstract][Full Text] [Related]
19. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.
Khan AA; Morrison A; Kendler DL; Rizzoli R; Hanley DA; Felsenberg D; McCauley LK; O'Ryan F; Reid IR; Ruggiero SL; Taguchi A; Tetradis S; Watts NB; Brandi ML; Peters E; Guise T; Eastell R; Cheung AM; Morin SN; Masri B; Cooper C; Morgan SL; Obermayer-Pietsch B; Langdahl BL; Dabagh RA; Davison KS; Sándor GK; Josse RG; Bhandari M; El Rabbany M; Pierroz DD; Sulimani R; Saunders DP; Brown JP; Compston J;
J Clin Densitom; 2017; 20(1):8-24. PubMed ID: 27956123
[TBL] [Abstract][Full Text] [Related]
20. Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review.
Raimondi A; Simeone N; Guzzo M; Maniezzo M; Collini P; Morosi C; Greco FG; Frezza AM; Casali PG; Stacchiotti S
ESMO Open; 2020 Jul; 5(4):. PubMed ID: 32661185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
